Stephen Wiviott

Stephen Wiviott

Harvard University

H-index: 98

North America-United States

About Stephen Wiviott

Stephen Wiviott, With an exceptional h-index of 98 and a recent h-index of 69 (since 2020), a distinguished researcher at Harvard University,

His recent articles reflect a diverse array of research interests and contributions to the field:

Concurrent Evaluation of hsTnI and hsTnT and Their Associations with Cardiovascular Events in 37,886 Patients with Stable Atherosclerotic Cardiovascular Disease

SGLT2 Inhibitors and Major Adverse Cardiovascular Events in Patients with Diabetes at High Risk For Atherosclerotic Cardiovascular Disease, Heart Failure or Chronic Kidney …

Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial

Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis

Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis

SOLUBLE SUPPRESSION OF TUMORIGENICITY 2 (SST2) AND CARDIOVASCULAR OUTCOMES IN PERSONS WITH TYPE 2 DIABETES MELLITUS RANDOMIZED TO DAPAGLIFLOZIN OR PLACEBO: ANALYSES FROM THE …

Stephen Wiviott Information

University

Position

Harvard Medical School

Citations(all)

90037

Citations(since 2020)

42524

Cited By

65497

hIndex(all)

98

hIndex(since 2020)

69

i10Index(all)

247

i10Index(since 2020)

190

Email

University Profile Page

Google Scholar

Top articles of Stephen Wiviott

Concurrent Evaluation of hsTnI and hsTnT and Their Associations with Cardiovascular Events in 37,886 Patients with Stable Atherosclerotic Cardiovascular Disease

Journal of the American College of Cardiology

2024/4/2

Petr Jarolim
Petr Jarolim

H-Index: 39

Stephen Wiviott
Stephen Wiviott

H-Index: 65

SGLT2 Inhibitors and Major Adverse Cardiovascular Events in Patients with Diabetes at High Risk For Atherosclerotic Cardiovascular Disease, Heart Failure or Chronic Kidney …

Journal of the American College of Cardiology

2024/4/2

Hiddo Lambers Heerspink
Hiddo Lambers Heerspink

H-Index: 64

Stephen Wiviott
Stephen Wiviott

H-Index: 65

Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial

European Journal of Preventive Cardiology

2024/3/14

Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis

JAMA cardiology

2024/2/28

Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis

Circulation

2024/4/7

SOLUBLE SUPPRESSION OF TUMORIGENICITY 2 (SST2) AND CARDIOVASCULAR OUTCOMES IN PERSONS WITH TYPE 2 DIABETES MELLITUS RANDOMIZED TO DAPAGLIFLOZIN OR PLACEBO: ANALYSES FROM THE …

Journal of the American College of Cardiology

2024/4/2

Stephen Wiviott
Stephen Wiviott

H-Index: 65

Petr Jarolim
Petr Jarolim

H-Index: 39

Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

The Lancet Diabetes & Endocrinology

2023/4/1

RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58

Journal of the American College of Cardiology

2023/3/7

Genetic Predisposition to Adiposity is Associated with Greater Risk of Subsequent Heart Failure Events in Individuals with Type 2 Diabetes Mellitus

International Journal of Obesity

2018/1

Risk of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients with Type 2 Diabetes Mellitus

Journal of the American College of Cardiology

2023/3/7

Andrea Bellavia
Andrea Bellavia

H-Index: 22

Stephen Wiviott
Stephen Wiviott

H-Index: 65

Reduction in Total Cardiovascular Events with the PCSK9 Inhibitor Evolocumab in Patients with Cardiovascular Disease in the Combined FOURIER and FOURIER Open-Label Extension …

Journal of the American College of Cardiology

2023/3/7

Stephen Wiviott
Stephen Wiviott

H-Index: 65

Dan Atar
Dan Atar

H-Index: 54

Bei Wang
Bei Wang

H-Index: 24

NT-PROBNP, BODY MASS INDEX, AND HEART FAILURE RISK IN CAMELLIA-TIMI 61

Journal of the American College of Cardiology

2023/3/7

Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis

European heart journal

2023/1/21

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

Diabetes care

2023/1/2

Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61

European Journal of Heart Failure

2023/12/22

Circulation Research Online First

Circulation Research

2023/12/14

Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3

Journal of Clinical Lipidology

2023/12/10

Performance of a Polygenic Risk Score for Coronary Artery Disease Across the Spectrum of ASCVD: An Analysis of 60k Patients From 6 TIMI Randomized Trials

Circulation

2023/11/7

See List of Professors in Stephen Wiviott University(Harvard University)